Departing Leo Pharma executive plans to follow Genmab's example for new biotech: "It's a major aspiration, but it's can be done"
Leo Pharma's departing head of R&D wants to create a pharmaceutical venture in his new position as the CEO of Union Therapeutics – inspired by Jan van de Winkel and Genmab.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
Kim Kjøller's decision to leave the role of Executive Vice President Global Research&Development at Leo Pharma in favor of a CEO position in a minor biotech firm partly owes to his vision of creating a new frontrunner in the Danish pharmaceutical industry.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Danish Covid-19 vaccine might be ready before 2021
For abonnenter
.jpg&w=384&q=75){kind=logo}
